多位抗凝剂通过药用血清的来调节:一种独特的天然策略来对抗血栓形成
Feng Shi1,2, Qingmei Hu1, Yiquan Lin1,2
1Engineering Research Center for Exploitation and Utilization of Leech Resources in Universities of Yunnan Province, School of Agriculture and Life Sciences, Kunming University, Kunming, 650214, China.
Pharmaceutical research
|December 16, 2025
概括
药用吸血虫提供了一种天然的,多目标的抗凝药方法,抑制了血液凝块形成的关键步骤. 这些水衍生的可以作为下一代抗血栓剂,降低风险.
科学领域:
- 生物化学和分子生物学
- 药理学 药理学 是一个学科.
- 基因组学就是基因组学.
背景情况:
- 血栓性疾病是全球健康面临的重大挑战.
- 现有的抗凝剂具有局限性,包括出血风险和狭窄的治疗窗口,由于单一向机制.
- 药用吸血虫拥有自然,可以调节多个静血路径.
研究的目的:
- 系统地审查关于水母衍生抗凝固的研究.
- 通过分子标和抗血栓机制来分类这些.
- 探索它们作为下一代抗血栓剂的潜力.
主要方法:
- 对生化学,结构学,功能学和奥米学研究的系统性文献综述.
- 根据它们的标和机制来分类水母衍生的.
- 分析omics数据以确定新候选者.
主要成果:
- 血清可以协同抑制血小板聚合和粘附.
- 他们直接准关键的凝血蛋白酶,如血栓素和XA因子.
- 干扰纤维素稳定,促进凝块溶解,与奥米克揭示扩展的抗血栓基因家族.
结论:
- 血清衍生提供了一个多目标抗凝平台.
- 这些是新型抗血栓治疗的有希望的线索.
- 整合传统和基因组学引导的发现将推动它们的发展.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K


